Cellular and molecular pharmacology of oxaliplatin

Molecular Cancer Therapeutics

Volumn 1, Issue 3, 2002, Pages 227-235

  Raymond, Eric ^a   Faivre, Sandrine ^a   Chaney, Stephen ^b   Woynarowski, Jan ^c   Cvitkovic, Esteban ^d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CTRC Institute for Drug Development   (United States)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; OXALIPLATIN; PLATINUM COMPLEX;

ANIMAL; BIOTRANSFORMATION; DNA ADDUCT; DNA REPAIR; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DNA ADDUCTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 0036052558     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Cvitkovic, E. A historical perspective on oxaliplatin: rethinking the role of platinum compounds and learning from near misses. Semin. Oncol., 25: 1-3, 1998.
2. Raymond, E., Chaney, S. G., Taamma, A., and Cvitkovic, E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol., 9: 1053-1071, 1998. (Pubitemid 28518143)
3. Raymond, E., Faivre, S., Woynarowski, J. M., and Chaney, S. G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol., 25: 4-12, 1998. (Pubitemid 28248696)
4. Soulié, P., Raymond, E., Brienza, S., and Cvitkovic, E. Oxaliplatin: the first DACH platinum in clinical practice. Bull. Cancer, 84: 665-673, 1997. (Pubitemid 27351535)
5. Cvitkovic, E. Ongoing and unsaid on oxaliplatin: the hope. Br. J. Cancer, 77 (Suppl. 4): 8-11, 1998.
6. Llory, J. F., Soulié, P., Cvitkovic, E., and Misset, J. L. Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin. J. Natl. Cancer Inst. (Bethesda), 86: 1098-1099, 1994. (Pubitemid 24228480)
7. Soulié, P., Bensmaine, A., Garrino, C., Chollet, P., Brain, E., Fereres, M., Jasmin, C., Musset, M., Misset, J. L., and Cvitkovic, E. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur. J. Cancer, 33: 1400-1406, 1997. (Pubitemid 27404897)
8. Kidani, Y., Iigo, M., Inagaki, K., Hoshi, A., and Kuretani, K. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J. Med. Chem., 21: 1315-1318, 1978. (Pubitemid 9093117)
9. Loehrer, P. J., Turner, S., Kubilis, P., Hui, S., Correa, J., Ansari, R., Stephens, D., Woodburn, R., and Meyer, S. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. J. Clin. Oncol., 6: 642-648, 1988.
10. Kemeny, N., Israel, K., Niedzwiecki, D., Chapman, D., Botet, J., Minsky, B., Vinciguerra, V., Rosenbluth, R., Bosselli, B., and Cochran, C. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J. Clin. Oncol., 8: 313-318, 1990. (Pubitemid 20056563)
11. Sasaki, K., Yamamitsu, S., Hirata, K., Koide, S., Takasaka, H., Hiraike, N., Katsuramaki, T., Denno, R., and Shirasaka, T. Combination chemotherapy of intermittent infusion 5-FU and CDDP for advanced colorectal adenocarcinoma: a Sapporo Cancer Study Trial. Proc. Am. Soc. Clin. Oncol., 17: 302a, 1998.
12. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol., 52: 1855-1865, 1996. (Pubitemid 26419675)
13. Pendyala, L., Kidani, Y., Perez, R., Wilkes, J., Bernacki, R. J., and Creaven, P. J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett., 97: 177-184, 1995.
14. Pendyala, L., and Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res., 53: 5970-5976, 1993. (Pubitemid 24006168)
15. Holmes, J., Stanko, J., Varchenko, M., Ding, H., Madden, V. J., Bagnell, C. R., Wyrick, S. D., and Chaney, S. G. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. J. Toxicol. Sci., 46: 342-351, 1998. (Pubitemid 29069619)
16. Raymond, E., Lawrence, R., Izbicka, E., Faivre, S., and Von Hoff, D. D. Activity of oxaliplatin against human tumor colony-forming units. Clin. Cancer Res., 4: 1021-1029, 1998. (Pubitemid 28183405)
17. Kraker, A., Steinkampf, R. W., and Moore, C. W. Transport of Cis-Pt and Cis-Pt analogs in sensitive and resistant murine leukemia cell lines. Proc. Am. Assoc. Cancer Res., 27: 286, 1986.
18. Fukuda, M., Ohe, Y., Kanzawa, F., Oka, M., Hara, K., and Saijo, N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res., 15: 393-398, 1995.
19. Raymond, E., Buquet-Fagot, C., Djelloul, S., Mester, J., Cvitkovic, E., Allain, P., Louvet, C., and Gespach, C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs, 8: 876-885, 1997. (Pubitemid 27487802)
20. Saris, C. P., van de Vaart, P. J. M., Rietbroek, R. C., and Blommaert, F. A. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis (Lond.), 17: 2763-2769, 1996. (Pubitemid 27037637)
21. Woynarowski, J. M., Faivre, S., Herzig, M. C., Arnett, B., Chapman, W. G., Trevino, A. V., Raymond, E., Chaney, S. G., Vaisman, A., Varchenko, M., et al. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol., 58: 920-927, 2000.
22. Woynarowski, J. M., Chapman, W. G., Napier, C., Herzig, M. C., and Juniewicz, P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol., 54: 770-777, 1998. (Pubitemid 28523169)
23. Luo, F. R., Wyrick, S. D., and Chaney, S. G. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol. Res., 10: 595-603, 1998. (Pubitemid 128740448)
24. Luo, F. R., Yen, T. Y., Wyrick, S. D., and Chaney, S. G. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J. Chromatogr. B Biomed. Sci. Appl., 724: 345-356, 1999. (Pubitemid 29148096)
25. Luo, F. R., Wyrick, S. D., and Chaney, S. G. Biotransformations of oxaliplatin in rat blood in vitro. J. Biochem. Mol. Toxicol., 13: 159-169, 1999. (Pubitemid 129705388)
26. Faivre, S., and Woynarowski, J. M. Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells. Proc. Am. Assoc. Cancer Res., 39: 158, 1998.
27. Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., and Chaney, S. G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res., 58: 3579-3585, 1998. (Pubitemid 28376554)
28. Reardon, J. T., Vaisman, A., Chaney, S. G., and Sancar, A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine- dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res., 59: 3968-3971, 1999. (Pubitemid 29393563)
29. Vaisman, A., Lim, S. E., Patrick, S. M., Copeland, W. C., Hinkle, D. C., Turchi, J. J., and Chaney, S. G. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry, 38: 11026-11039, 1999.
30. Scheeff, E. D., Briggs, J. M., and Howell, S. B. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol. Pharmacol., 56: 633-643, 1999. (Pubitemid 29406890)
31. Sharp, S. Y., O'Neill, C. F., Boxall, F., Rogers, P., Stephens, T., and Kelland, L. R. Non-cross resistance between oxaliplatin and ZD0473 in acquired oxaliplatin-resistant colon and ovarian carcinoma cell lines. Clin. Cancer Res. (suppl.), 6: 4537s, 2000.
32. Damia, G., Guidi, G., and D'Incalci, M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur. J. Cancer, 34: 1783-1788, 1998. (Pubitemid 28474236)
33. Hibino, Y., Hiraoka, Y., Kamiuchi, S., Kusashio, E., and Sugano, N. Enhancement of excision repair of cisplatin-DNA adducts by cell-free extract from a cisplatin-resistant rat cell line. Biochem. Pharmacol., 57: 1415-1422, 1999. (Pubitemid 29225105)
34. Petersen, L. N., Mamenta, E. L., Stevnsner, T., Chaney, S. G., and Bohr, V. A. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines and studies on carrier ligand specificity. Carcinogenesis (Lond.), 17: 2597-2602, 1996. (Pubitemid 27037614)
35. Issa, J. P. The epigenetics of colorectal cancer. Ann. N. Y. Acad. Sci., 910: 140-153, 2000.
36. Thibodeau, S. N., French, A., Roche, P., Cunningham, J., Tester, D., Lindor, N., Moslein, G., Baker, S., Liskay, R., Burgart, L., et al. Altered expression of hMSH2 and hMSH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res., 56: 4836-4840, 1996. (Pubitemid 26374414)
37. Wheeler, J. M., Beck, N. E., Kim, H. C., Tomlinson, I. P., Mortensen, N. J., and Bodmer, W. F. Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: the predominant role of hMLH1. Proc. Natl. Acad. Sci. USA, 96: 10296-10301, 1999. (Pubitemid 29422552)
38. Kuismanen, S. A., Holmberg, M. T., Salovaara, R., Schweizer, P., Aaltonen, L. A., de la, C. A., Nystrom-Lahti, M., and Peltomaki, P. Epigenetic phenotypes distinguish microsatellite-stable and -unstable colorectal cancers. Proc. Natl. Acad. Sci. USA, 96: 12661-12666, 1999. (Pubitemid 29513559)
39. Herman, J., Umar, A., Polyak, K., Graff, J., Ahuja, N., Issa, J., Markowitz, S., Willson, J., Hamilton, S. R., and Kinzler, K. W., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998. (Pubitemid 28278073)
40. Thibodeau, S. N., French, A., Cunningham, J., Tester, D., Burgart, L., Roche, P., McDonnel, S., Schaid, D., Vockely, C., Michels, V., et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res., 58: 1713-1718, 1998. (Pubitemid 28215098)
41. Strathdee, G., Mackean, M., Illand, M., and Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene, 18: 2335-2341, 1999. (Pubitemid 29192710)
42. Kuismanen, S. A., Holmberg, M. T., Salovaara, R., de la, C. A., and Peltomaki, P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am. J. Pathol., 156: 1773-1779, 2000. (Pubitemid 30646714)
43. King, B. L., Carcangiu, M. L., Carter, D., Kiechle, M., Pfisterer, J., Pfleiderer, A., and Kacinski, B. M. Microsatellite instability in ovarian neoplasms. Br. J. Cancer, 72: 376-382, 1995.
44. Kolodner, R. D. Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem. Sci., 20: 397-401, 1995.
45. Paulson, T. G., Wright, F. A., Parker, B. A., Russack, V., and Wahl, G. M. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res., 56: 4021-4026, 1996. (Pubitemid 26284754)
46. Herfarth, K. K., Kodner, I. J., Whelan, A. J., Ivanovich, J. L., Bracamontes, J. R., Wells, S. A., Jr., and Goodfellow, P. J. Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers with microsatellite instability. Genes Chromosomes Cancer, 18: 42-49, 1997. (Pubitemid 27020255)
47. Brown, R., Hirst, G. L., Gallagher, W., Mcllwrath, A., Margison, G. P., van der Zee, A., and Anthoney, D. A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15: 45-52, 1997. (Pubitemid 27348095)
48. Mackay, H. J., Cameron, D., Rahilly, M., Mackean, M. J., Paul, J., Kaye, S. B., and Brown, R. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J. Clin. Oncol., 18: 87-93, 2000. (Pubitemid 30036340)
49. Herman, J., Umar, A., Polyak, K., Graff, J., Ahuja, N., Issa, J. P., Markowitz, S., Willson, J., Hamilton, S. R., Kinzler, K. W., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998. (Pubitemid 28278073)
50. Brown, R., Hirst, G. L., Gallagher, W., Mcllwrath, A., Margison, G. P., van der Zee, A., and Anthoney, D. A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15: 45-52, 1997. (Pubitemid 27348095)
51. Plumb, J. A., Strathdee, G., Sludden, J., Kaye, S., and Brown, R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5- azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res., 60: 6039-6044, 2000.
52. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996. (Pubitemid 26199755)
53. Ferry, K. V., Fink, D., Johnson, S. W., Nebel, S., Hamilton, T. C., and Howell, S. B. Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells. Biochem. Pharmacol., 57: 861-867, 1999. (Pubitemid 29127097)
54. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996. (Pubitemid 26374423)
55. Strathdee, G., Mackean, M. J., Illand, M., and Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene, 18: 2335-2341, 1999. (Pubitemid 29192710)
56. Strathdee, G., Appleton, K., Illand, M., Millan, D. W., Sargent, J., Paul, J., and Brown, R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol., 158: 1121-1127, 2001. (Pubitemid 32221804)
57. de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., Andre, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
58. Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T. P., Nehme, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res., 57: 1841-1845, 1997. (Pubitemid 27209707)
59. Nebel, S., Fink, D., Nehme, A., Aebi, S., Christen, R. D., and Howell, S. B. Role of the DNA mismatch repair proteins in the recognition of platinum DNA adducts. Proc. Am. Assoc. Cancer Res., 38: 359, 1997.
60. Nehme, A., Baskaran, R., Nebel, S., Fink, D., Howell, S. B., Wang, J. Y., and Christen, R. D. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br. J. Cancer, 79: 1104-1110, 1999. (Pubitemid 29087882)
61. Moreland, N. J., Illand, M., Kim, Y. T., Paul, J., and Brown, R. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res., 59: 2102-2106, 1999. (Pubitemid 29217672)
62. Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C., Hirst, G. L., Borts, R. H., and Brown, R. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr. Biol., 9: 51-54, 1999. (Pubitemid 29045795)
63. Akaboshi, M., Kawai, K., Ujeno, Y., Takada, S., and Miyahara, T. Binding characteristics of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobu- tanedicarboxylato)-2-platinum(II) to DNA, RNA and protein molecules in HeLa cells and its lethal effect: comparison with cis- and trans- diamminedichloroplatinums(II). Jpn. J. Cancer Res., 85: 106-111, 1994. (Pubitemid 24048298)
64. Akaboshi, M., Kawai, K., Maki, H., Akuta, K., Ujeno, Y., and Miyahara, T. The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn. J. Cancer Res., 83: 522-526, 1992.
65. Woynarowski, J. M., Koester, S., Woynarowska, B., Arnett, B., Trevino, A. V., Chan, D., Higdon, A., Munoz, R., Herzig, M. C., and Faivre, S. Is drug-induced damage sufficient for apoptosis induction? Proc. Am. Assoc. Cancer Res., 40: 736, 1999.
66. Chaney, S., and Sancar, A. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. (Bethesda), 88: 1346-1360, 1996. (Pubitemid 26329752)
67. Graham, M., Lockwood, G., Greenslade, D., Brienza, S., Bayssas, M., and Gamelin, E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res., 6: 1205-1218, 2000. (Pubitemid 30226200)
68. Misset, J. L., Bleiberg, H., Sutherland, W., Bekradda, M., and Cvitkovic, E. Oxaliplatin clinical activity: a review. Crit. Rev. Oncol. Hematol., 35: 75-93, 2000. (Pubitemid 30599431)
69. Mavroudis, D., Kourousis, C., Kakolyris, S., Agelaki, S., Kalbakis, K., Androulakis, N., Souglakos, J., Vardakis, N., Samonis, G., and Georgoulias, V. Phase I study of gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. Semin. Oncol., 27: 25-30, 2000. (Pubitemid 30108681)
70. Carethers, J. M., Chauhan, D. P., Fink, D., Nebel, S., Bresalier, R. S., Howell, S. B., and Boland, C. R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology, 117: 123-131, 1999. (Pubitemid 29297628)
71. Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., and Boothman, D. A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res., 61: 5193-5201, 2001. (Pubitemid 32681553)
72. Plasencia, C., Taron, M., Martinez, E., Rossell, R., and Abad, A. Down-regulation of thymidylate synthase gene expression after oxaliplatin administration: implications for the synergistic activity of sequential oxaliplatin/5FU in sensitive and 5FU-resistant cell lines. Proc. Am. Assoc. Cancer Res., 42: 508, 2001.
73. Fischel, J. L., Etienne, M. C., Formento, P., and Milano, G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin. Cancer Res., 4: 2529-2535, 1998. (Pubitemid 28477921)
74. Metzger, G., Massari, C., Etienne, M. C., Comisso, M., Brienza, S., Touitou, Y., Milano, G., Bastian, G., Misset, J. L., and Levi, F. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin. Pharmacol. Ther., 56: 190-201, 1994. (Pubitemid 24274186)
75. Gale, G. R., Loretta, M., Atkins, L. M., Schwartz, P., and Meischen, S. J. Potentiating action of 5-fluorouracil when used in combination with platinum compounds and cyclophosphamide in treatment of advanced L1210 leukemia. Bioinorg. Chem., 8: 445-451, 1978. (Pubitemid 8359060)
76. Ducreux, M., Louvet, C., Bekradda, M., and Cvitkovic, E. Oxaliplatin for the treatment of advanced colorectal cancer: future directions. Semin. Oncol., 25: 47-53, 1998. (Pubitemid 28248701)
77. Louvet, C., Raymond, E., Coudray, A. M., Chazard, M., and Gespach, C. Antitumor activity of UFT + folinic acid (FA) in combination with oxaliplatin (Ox) against human HT29 colon cancer xenografts in athymic nude mice. Proc. Am. Assoc. Cancer Res., 40: 292, 1999.
78. Raymond, E., Djelloul, S., Buquet-Fagot, C., Goldwasser, F., Mester, J., Cvitkovic, E., Louvet, C., and Gespach, C. Oxaliplatin (LOHP), and cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694), and topoisomerase I (TOPO-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers (meeting abstract). Proc. Am. Assoc. Cancer Res., 37: 291, 1996.
79. Faivre, S., Raymond, E., Woynarowski, J. M., and Cvitkovic, E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother. Pharmacol., 44: 117-123, 1999. (Pubitemid 29297057)
80. Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R. D., and Howell, S. B. P53 modulates the effects of loss of DNA mismatch repair on sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res., 61: 1508-1516, 2001. (Pubitemid 34292580)
81. Mathe, G., Chenu, E., Bourut, C., and Florentin, I. Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia. Proc. Am. Assoc. Cancer Res., 30: 471, 1989.
82. Mathe, G., Kidani, Y., Segiguchi, M., Eriguchi, M., Fredj, G., Peytavin, G., Misset, J. L., Brienza, S., de Vassals, F., and Chenu, E. Oxalatoplatinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother., 43: 237-250, 1989. (Pubitemid 19153975)
83. Goldwasser, F., Bozec, L., Zeghari-Squalli, N., and Misset, J. L. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs, 10: 195-201, 1999. (Pubitemid 29141306)
84. Zeghari-Squalli, N., Raymond, E., Cvitkovic, E., and Goldwasser, F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res., 5: 1189-1196, 1999. (Pubitemid 29233237)
85. Bissery, M. C., Vrignaud, P., and Lavelle, F. In vivo evaluation of the irinotecan-oxaliplatin combination. Proc. Am. Assoc. Cancer Res., 39: 526, 1998.
86. Mailliet, P., Segal-Bendirdjian, E., Kozelka, J., Barreau, M., Baudoin, B., Bissery, M. C., Gontier, S., Laoui, A., Lavelle, F., and Le Pecq, J. B. Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships. Anticancer Drug Des., 10: 51-73, 1995.
87. Skou, G., Mangold, G., Dexter, D., and Von Hoff, D. D. Comparison of an oxaliplatin-taxol versus carboplatin-taxol regimen in the treatment of the MV-522 human lung tumor xenograft. Proc. Am. Assoc. Cancer Res., 37: 375, 1996.
88. Debner, J., Dexter, D., Mangold, G., Juniewicz, P., Rake, J., and Von Hoff, D. D. Evaluation of oxaliplatin-tirapazamine-taxol combinations in the MV-522 human lung carcinoma xenograft model. Proc. Am. Assoc. Cancer Res., 38: 312, 1997.
89. Faivre, S., Kalla, S., Cvitkovic, E., Bourdon, O., Hauteville, D., Dourte, L. M., Bensmaine, A., Itzhaki, M., Marty, M., and Extra, J. M. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate use experience. Ann. Oncol., 10: 1125-1128, 1999. (Pubitemid 29482472)
90. Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., Bertheaut-Cvitkovic, F., Larregain-Fournier, D., Le Rol, A., Walter, S., Adam, R., Misset, J. L., and Levi, F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 18: 136-147, 2000. (Pubitemid 30036347)
91. De Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 18: 2938-2947, 2000. (Pubitemid 30644117)
92. Fizazi, K., Ducreux, M., Ruffie, P., Bonnay, M., Daniel, C., Soria, J. C., Hill, C., Fandi, A., Poterre, M., Smith, M., et al. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J. Clin. Oncol., 18: 2293-2300, 2000. (Pubitemid 30350222)
93. Wasserman, E., Cuvier, C., Lokiec, F., Goldwasser, F., Kalla, S., Méry-Mignard, D., Ould Kaci, M., Bensmaine, A., Dupont-André, G., Mahjoubi, M., et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J. Clin. Oncol., 17: 1751-1759, 1999. (Pubitemid 29269244)
94. Scheithauer, W., Kornek, G. V., Raderer, M., Valencak, J., Weinlander, G., Hejna, M., Haider, K., Kwasny, W., and Depisch, D. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J. Clin. Oncol., 17: 902-906, 1999. (Pubitemid 29109321)
95. Kemeny, N., Tong, W., Stockman, J., Blanchette, J., and Saltz, L. Phase I trial of weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 19: 245a, 2000.
96. Goldwasser, F., Gross-Goupil, M., Tigaud, J. M., Di Palma, M., Marceau-Suissa, J., Wasserman, E., Yovine, A., Misset, J. L., and Cvitkovic, E. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. Ann. Oncol., 11: 1463-1470, 2000.
97. Misset, J. L., Goldwasser, F., Riofrio, M., Gross, M., Romain, D., and Lokiec, F. Topotecan-oxaliplatin every three weeks: a phase I and pharmacological study. Proc. Am. Soc. Clin. Oncol., 18: 220a, 1999.
98. Delaloge, S., Laadem, A., Chouaki, N., Pautier, P., Taamma, A., Misset, J. L., Cvitkovic, E., and Lhomme, C. Feasibility study of the paclitaxel (PXL), oxaliplatin (LOHP) and ciplatin (CDDP) combination in advanced ovarian cancer (AOC). Proc. Am. Soc. Clin. Oncol., 18: 365a, 1999.
99. Buechele, T., Schmoll, H., Grothey, A., and Voigt, W. Biweekly Docetaxel (Doc), Gemcitabine (Gem), Oxaliplatin (LOHP) in heavily pretreated patients with solid tumors-a pilot study. Proc. Am. Soc. Clin. Oncol., 18: 205a, 1999.
100. el-akawi, Z., Abu-hadid, M., Perez, R., Glavy, J., Zdanowicz, J., Creaven, P. J., and Pendyala, L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett., 105: 5-14, 1996.